Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment
Abstract
:1. Introduction
2. Personalized Cancer Treatment Using Genomic Profiling
2.1. The Current Status of Cancer Precision Medicine
2.2. Using EUS-Guided Sampling to Improve Personalized Treatment for PDAC
2.3. Cancer Genomic Medicine for PDAC: A Future Perspective
3. Personalized Cancer Treatment Using Pharmacological Profiling
3.1. Effectiveness and Role of Chemosensitivity Tests for PDAC Treatment
3.2. Patient-Derived Tumor Organoids for PDAC: A Future Perspective
3.3. EUS-Guided Sampling for Personalized Medicine Using PDOs
3.4. Human PDOs Establishment from EUS-Guided Sampling
3.5. High Throughput Drug Screening Test Using PDOs
3.6. Drug Screening Test for PDAC Using Organoids
4. Additional Diagnostic Methods for PDACs
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vincent, A.; Herman, J.; Schulick, R.; Hruban, R.H.; Goggins, M. Pancreatic cancer. Lancet 2011, 378, 607–620. [Google Scholar] [CrossRef]
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021, 71, 7–33. [Google Scholar] [CrossRef] [PubMed]
- Pishvaian, M.J.; Blais, E.M.; Brody, J.R.; Lyons, E.; DeArbeloa, P.; Hendifar, A.; Mikhail, S.; Chung, V.; Sahai, V.; Sohal, D.P.S.; et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020, 21, 508–518. [Google Scholar] [CrossRef]
- Li, D.F.; Wang, J.Y.; Yang, M.F.; ** of human pancreatic cancer organoids. Stem Cells Int. 2019, 2019, 1024614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bode, K.J.; Mueller, S.; Schweinlin, M.; Metzger, M.; Brunner, T. A fast and simple fluorometric method to detect cell death in 3D intestinal organoids. Biotechniques 2019, 67, 23–28. [Google Scholar] [CrossRef] [Green Version]
- Frappart, P.O.; Hofmann, T.G. Pancreatic ductal adenocarcinoma (Pdac) organoids: The shining light at the end of the tunnel for drug response prediction and personalized medicine. Cancers 2020, 12, 2750. [Google Scholar] [CrossRef] [PubMed]
- Brand, R.E.; Adai, A.T.; Centeno, B.A.; Lee, L.S.; Rateb, G.; Vignesh, S.; Menard, C.; Wiechowska-Kozłowska, A.; Bołdys, H.; Hartleb, M.; et al. A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer. Clin. Gastroenterol. Hepatol. 2014, 12, 1717–1723. [Google Scholar] [CrossRef]
- Ungureanu, B.S.; Pirici, D.; Dima, S.O.; Popescu, I.; Hundorfean, G.; Surlin, V.; Saftoiu, A. Morphometric assessment of confocal laser endomicroscopy for pancreatic ductal adenocarcinoma, an ex-vivo pilot study. Diagnostics 2020, 10, 923. [Google Scholar] [CrossRef]
- Underwood, P.W.; Gerber, M.H.; Nguyen, K.; Delitto, D.; Han, S.; Thomas, R.M.; Forsmark, C.E.; Trevino, J.G.; Gooding, W.E.; Hughes, S.J. Protein signatures and tissue diagnosis of pancreatic cancer. J. Am. Coll. Surg. 2020, 230, 26–36.e1. [Google Scholar] [CrossRef] [Green Version]
- Ashizawa, K.; Yoshimura, K.; Johno, H.; Inoue, T.; Katoh, R.; Funayama, S.; Sakamoto, K.; Takeda, S.; Masuyama, K.; Matsuoka, T.; et al. Construction of mass spectra database and diagnosis algorithm for head and neck squamous cell carcinoma. Oral Oncol. 2017, 75, 111–119. [Google Scholar] [CrossRef] [PubMed]
- Yoshimura, K.; Mandal, M.K.; Hara, M.; Fujii, H.; Chen, L.C.; Tanabe, K.; Hiraoka, K.; Takeda, S. Real-time diagnosis of chemically induced hepatocellular carcinoma using a novel mass spectrometry-based technique. Anal. Biochem. 2013, 441, 32–37. [Google Scholar] [CrossRef] [PubMed]
- Mandal, M.K.; Yoshimura, K.; Chen, L.C.; Yu, Z.; Nakazawa, T.; Katoh, R.; Fujii, H.; Takeda, S.; Nonami, H.; Hiraoka, K. Application of probe electrospray ionization mass spectrometry (PESI-MS) to clinical diagnosis: Solvent effect on lipid analysis. J. Am. Soc. Mass Spectrom. 2012, 23, 2043–2047. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chung, W.Y.; Correa, E.; Yoshimura, K.; Chang, M.C.; Dennison, A.; Takeda, S.; Chang, Y.T. Using probe electrospray ionization mass spectrometry and machine learning for detecting pancreatic cancer with high performance. Am. J. Transl. Res. 2020, 12, 171–179. [Google Scholar]
Authors and Year | Method of Sampling and Type of Needle | Number of Patients | Successfully Sequenced Samples, n (%) |
---|---|---|---|
Larson et al. [10], 2018 | EUS-FNB EUS-FNA Percutaneous | 54 7 8 | 38 (70.4%) 3 (42.9%) 8 (100%) |
Hayashi et al. [40], 2018 | EUS-FNA (FFPE) 22-G | 9 | 7 (78%) Re-biopsy 2 (22%) |
Elhanafi et al. [46], 2020 | EUS-FNB 22-G EUS-FNA 22-G | 22 145 | 20 (90.9%) 97 (66.9%) |
Semaan et al. [47], 2020 | EUS-FNA (cytology) | ND | 23 (ND) |
Kandel et al. [6], 2020 | EUS-FNB (fresh frozen) EUS-FNA (fresh frozen) 19-G for body and tail/22-G for head | 50 50 | 39 (78%) 7 (14%) |
Authors, Year | Method of Sampling/Type of Needle | Number of Patients | Number of Organoids Created n (%) |
---|---|---|---|
Boj et al. [70], 2015 | FNA/ND | ND | 2 (primary and metastasis) |
Tiriac et al. [62], 2018 | FNB/22-G | 60 | 43 (71%) |
Seino et al. [61], 2019 | FNB/22-G | ND | 27 (ND) |
Bian et al. [71], 2019 | FNB/ND | ND | 24 (85%) |
Henning et al. [75] 2019 | FNA/ND | 6 | 5 (83%) |
Vilgelm et al. [72], 2020 | FNA/25-G | 5 | 5 (ex vivo tumor, 100%) |
Juiz et al. [73], 2020 | ND | ND | 20 (ND) |
Lacomb et al. [74], 2020 | FNB/22-G 1 pass FNB/22-G 2 pass | 25 42 | 22 (88%) 34 (81%) |
Authors, Year | ECM-Matrix | Medium |
---|---|---|
Tiriac et al., 2018 [8] | Matrigel 100% Dome-type | Advanced DMEM/F12, HEPES (10 mM), Glutamax (1X), A83-01 (500 nM), hEGF (50 ng/mL), mNoggin (100 ng/mL), hFGF10 (100 ng/mL), hGastrin I (10 nM), N-acetylcysteine (1.25 mM), Nicotinamide (10 mM), PGE2 (1 μM), B27 supplement (1X), R-spondin-1 (10%), Afamin/Wnt3A (50%). |
Seino et al., 2018 [61] | GFR-Matrigel 100% Dome-type | Advanced DMEM/F12, HEPES (10 mM), Glutamax (2 mM), B27 (1X), Gastrin I (10 nM), N-acetylcysteine (1 mM), mEGF (50 ng/mL), mNoggin (100 ng/mL), R-spondin-1 (10%), Afamin-Wnt-3A (25%), A83-01 (500 nM), SB202190 (10 μM). |
Bian et al., 2019 [71]/Juiz et al., 2020 [73] | GFR-Matrigel 100% Dome-type | Advanced DMEM/F12, HEPES (10 mM), Glutamax (1X), hFGF10 (100 ng/mL); hEGF (50 ng/mL), hNoggin (100 ng/mL), Wnt3a (30%), R-spondin-1 (10%), hGastrin I (10 nM), Nicotinamide (10 mM), N-acetylcysteine (1.25 mM), B27 (1X); A83-01 (500 nM); Y27632 (10.5 µM). |
Hennig et al., 2019 [75] | GFR-Matrigel Dome-type | DMEM/F12, Wnt3a (50%), HEPES (1X), Pen/Strep (1X), and 1x Glutamax (1X), Noggin (10%), R-spondin-1 (10%), B27 (1X), Nicotinamide (10 mM), gastrin (1 nM), N-acetyl-L-cysteine (1 mM), Primocin (1 mg/mL), mEGF (50 ng/mL), hFGF10 (100 ng/mL), A-83-01 (0.5 μM), N2 (1X). |
Authors, Year | Plate | Number of Seeded Cells | Timing of Assay | Assay Method | Target Agents | No of PDOs |
---|---|---|---|---|---|---|
Tiriac et al., 2018 [8] | 96 well | 500 cells/well | 5 days after administration. | CellTiter-Glo® (luminescence ATP) | 5 | 66 |
Driehuis et al., 2019 [56] | 384 well | ND | 3 days after administration. | CellTiter-Glo® (luminescence ATP) | 76 | 24 |
Frappart et al., 2020 [77] | 96 well | 2000 cells/well | 4 days after administration. | CytoTox-GloTM (luminescence non-ATP) | 22 | 21 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Iwasaki, E.; Fukuhara, S.; Horibe, M.; Kawasaki, S.; Seino, T.; Takimoto, Y.; Tamagawa, H.; Machida, Y.; Kayashima, A.; Noda, M.; et al. Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment. Diagnostics 2021, 11, 469. https://doi.org/10.3390/diagnostics11030469
Iwasaki E, Fukuhara S, Horibe M, Kawasaki S, Seino T, Takimoto Y, Tamagawa H, Machida Y, Kayashima A, Noda M, et al. Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment. Diagnostics. 2021; 11(3):469. https://doi.org/10.3390/diagnostics11030469
Chicago/Turabian StyleIwasaki, Eisuke, Seiichiro Fukuhara, Masayasu Horibe, Shintaro Kawasaki, Takashi Seino, Yoichi Takimoto, Hiroki Tamagawa, Yujiro Machida, Atsuto Kayashima, Marin Noda, and et al. 2021. "Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment" Diagnostics 11, no. 3: 469. https://doi.org/10.3390/diagnostics11030469